Daniel D. Gretler
Corporate Officer/Principal at Stanford University
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Kryzwicki | M | - |
Stanford University
| 7 years |
| Pin Pin Tea-Mankorn | F | - |
Stanford University
| 10 years |
| John J. Schembri | M | 62 |
COR Therapeutics, Inc.
 COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 4 years |
| Joel Dudley | M | - |
Stanford University
| 4 years |
| Jonathan Hsu | M | - |
Stanford University
| 5 years |
| Ben Daniel | M | - |
Stanford University
| 1 years |
| Seth Silverman | M | - |
Stanford University
| 5 years |
| Clancey Stahr | M | - |
Stanford University
| 4 years |
| Christopher E Olin | M | - |
Stanford University
| 7 years |
| Nathan Nolop | M | - |
Stanford University
| 11 years |
| Sahil Bloom | M | - |
Stanford University
| 4 years |
| Enrique Zambrano | M | - |
Stanford University
| 7 years |
| Haomiao Huang | M | - |
Stanford University
| 7 years |
| Geoffrey Woo | M | - |
Stanford University
| 4 years |
| Iveshu Bhatia | M | - |
Stanford University
| 1 years |
| Jung-il Choi | M | - |
Stanford University
| 6 years |
| Chase Beeler | M | - |
Stanford University
| 5 years |
| Mada Seghete | F | - |
Stanford University
| 8 years |
| Karen Martell | F | - |
Stanford University
| 4 years |
| Lisa Hersch | F | - |
Stanford University
| 2 years |
| Elaine Zelby | F | - |
Stanford University
| 5 years |
| Joseph Lau | M | - |
Stanford University
| 4 years |
| Artem Barsukov | M | - |
Stanford University
| 3 years |
| Argyrios Zymnis | M | - |
Stanford University
| 5 years |
| Vic Miller | M | - |
Stanford University
| 4 years |
| Petr Johanes | M | - |
Stanford University
| 12 years |
| Guillaume Horel | M | - |
Stanford University
| 4 years |
| Andreas Eckner | M | - |
Stanford University
| 4 years |
| David McColl | M | - |
Stanford University
| 6 years |
| Forrest White | M | - |
Stanford University
| 5 years |
| Christina Ho | F | - |
Stanford University
| 5 years |
| Leeor Mushin | M | - |
Stanford University
| 2 years |
| Sampath Jinadasa | M | - |
Stanford University
| 5 years |
| Ibrahim Almojel | M | - |
Stanford University
| 6 years |
| Edward Segal | M | - |
Stanford University
| 4 years |
| Artem Trotsyuk | M | - |
Stanford University
| 4 years |
| Haithem Turki | M | - |
Stanford University
| 7 years |
| Alisha Adam | F | - |
Stanford University
| 5 years |
| Kristen Wong | F | - |
Stanford University
| 4 years |
| Wesley Lim | M | - |
Stanford University
| 4 years |
| Gülin Yilmaz | F | - |
Stanford University
| 4 years |
| John Melas-Kyriazi | M | - |
Stanford University
| 4 years |
| Michael Paulus | M | - |
Stanford University
| 5 years |
| Manu Lakkur | M | - |
Stanford University
| 5 years |
| Charles Homcy | M | 75 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 14 years |
| Peter Moran | M | - |
Stanford University
| 4 years |
| James Topper | M | 62 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 4 years |
| Hugh Browne | M | - |
Stanford University
| 2 years |
| R. Lee Douglas | M | 72 |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | 10 years |
| Jenny P. Chen | F | - |
Stanford University
| 6 years |
| Stephen M. McConnell | M | - |
The University of Chicago
| 1 years |
| Jon Cheek | M | - |
Stanford University
| 7 years |
| Renata Streit Quintini | F | - |
Stanford University
| 4 years |
| James P. McGillicuddy | M | - |
Stanford University
| 5 years |
| Rapp Alyssa | F | 45 |
Stanford University
| 2 years |
| Lou Fernandes | M | - |
Stanford University
| 2 years |
| Djalil Reghis | M | - |
Stanford University
| 2 years |
| Mike Rothenberg | M | - |
Stanford University
| 5 years |
| Nafis Jamal | M | - |
Stanford University
| 7 years |
| Nathan Evans | M | - |
Stanford University
| 6 years |
| Martin Casado | M | - |
Stanford University
| 6 years |
| Thomas P. Chung | M | - |
Stanford University
| 4 years |
| David H. Beisel | M | - |
Stanford University
| 2 years |
| Jessica Verrilli | F | - |
Stanford University
| 4 years |
| David S. Glynn | M | - |
Stanford University
| 2 years |
| Anthony J. Limberis | M | - |
Stanford University
| 2 years |
| Stephen Westwell | M | 66 |
Stanford University
| 1 years |
| Robert W. C. Davies | M | 49 |
Stanford University
| 2 years |
| Kirk Wolfe | M | - |
Stanford University
| 2 years |
| Matthew L. Garibaldi | M | - |
Stanford University
| 2 years |
| Megan V. Hansen | F | - |
Stanford University
| 4 years |
| Rafal Styczen | M | 53 |
Stanford University
| 1 years |
| Rhett Neuenschwander | M | - |
Stanford University
| 2 years |
| Hoda Alibair | F | - |
Stanford University
| 2 years |
| Na Xin Yao | M | 54 |
Stanford University
| 2 years |
| Brad Pereira | M | - |
Stanford University
| 4 years |
| Neil William Flanzraich | M | 80 |
Syntex (USA), Inc.
 Syntex (USA), Inc. Pharmaceuticals: MajorHealth Technology Part of Roche Bay Plc, Syntex (USA), Inc. is a company that manufactures and wholesales pharmaceutical products. The company is based in Palo Alto, CA. | 1 years |
| Daniel Goldberger | M | 65 |
Stanford University
| 1 years |
| Reshma Karipineni | F | - |
Stanford University
| 2 years |
| Kate Jackson Hobbs | F | - |
Stanford University
| 2 years |
| Eric Kroll | M | - |
Stanford University
| 2 years |
| Amr Awadallah | M | - |
Stanford University
| 3 years |
| Lauren Gross | F | - |
Stanford University
| 4 years |
| Piotr Andrzej Wianecki | M | - |
Stanford University
| 4 years |
| Paul Strachman | M | - |
Stanford University
| 2 years |
| Jason Hsiao Chen | M | - |
Stanford University
| 1 years |
| Jonathan Montagu | M | - |
Stanford University
| 2 years |
| Christopher T. Estreich | M | - |
Stanford University
| 4 years |
| Kathryn Hume | M | - |
Stanford University
| 5 years |
| Naomi Pilosof Ionita | F | - |
Stanford University
| 2 years |
| Yuval Grill | M | - |
Stanford University
| 2 years |
| Nicholas Hsu | M | - |
Stanford University
| 4 years |
| Parag Agrawal | M | 40 |
Stanford University
| 3 years |
| Saeko Goto | F | 49 |
Stanford University
| 1 years |
| Susan Li | F | 38 |
Stanford University
| 4 years |
| Betty Vo | F | - |
Stanford University
| 4 years |
| Lee Ward | M | - |
Stanford University
| 5 years |
| Meredith Nelson | F | - |
Stanford University
| 4 years |
| Carolyn Janiak Earthy | F | - |
Stanford University
| 3 years |
| Ethan Bing | M | - |
Stanford University
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Daniel D. Gretler
- Personal Network
